The Efficacy of Tranexamic Acid in Preventing Postpartum Haemorrhage After Caesarean Section

• Status: Recruiting
• Trial end date: 2021-12-31
• Target enrollment: 0
• Participant gender: Female

Summary

This study seeks to determine if the using tranexamic acid prophylactically at caesarean section will prevent postpartum haemorrhage which is a major cause of maternal mortality in Zimbabwe and globally.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Zimbabwe
• Collaborator: Fogarty International Center of the National Institute of Health
• Treatments: Tranexamic Acid

Criteria

Inclusion Criteria: Women undergoing elective or emergency caesarean section with:

• Estimated gestational age of 37 weeks or more

• Live intrauterine foetus

• Elective or emergency caesarean delivery

• Signed informed consent

Exclusion Criteria:

• History of coagulopathies or conditions predisposing them to thromboembolic phenomena,

• seizure history,

• autoimmune disease,

• placental abruption,

• placenta praevia,

• abnormally adherent placentae if identified on prenatal ultrasound,

• eclampsia or HELLP syndrome,

• known hypersensitivity to TXA,

• planned general anaesthesia,

• caesarean delivery for the second twin or second/third triplet(s) after vaginal birth of the first twin,

• poor understanding of English/Shona languages,

• those who have received anticoagulants in the week before delivery

• persons-under-investigation for Coronavirus disease (COVID-19) and confirmed COVID-19 positive women